<DOC>
	<DOC>NCT00060996</DOC>
	<brief_summary>The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to determine the effect of Remodulin on wound healing and treadmill walk distance.</brief_summary>
	<brief_title>Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Patients with Stage III or IV critical limb ischemia due to documented peripheral arterial disease with no planned interventional vascular procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>UT-15</keyword>
	<keyword>Remodulin</keyword>
	<keyword>treprostinil</keyword>
</DOC>